SOURCE: Altair Nanotechnologies

June 20, 2008 07:00 ET

Terry Copeland Appointed President and Chief Executive Officer of Altair Nanotechnologies

RENO, NV--(Marketwire - June 20, 2008) - Altair Nanotechnologies Inc. (NASDAQ: ALTI), a leading provider of advanced nanomaterials technology for use in energy, life sciences and industrial applications, today announced that its Board of Directors has appointed Terry Copeland, Ph.D., as its President and Chief Executive Officer. Dr. Copeland has been serving as interim President since March 2008.

"Terry's understanding of the company's personnel, products and market opportunities, combined with the breadth of his management expertise, make him the best choice to lead Altair Nanotechnologies in its next phase of growth," said Altair Board Chairman Jon N. Bengtson. "During the past 10 weeks, Terry and his newly formed executive team have reviewed the company's strategy, products and business units to assure Altair's proper positioning within its marketplaces. During this process Terry demonstrated in-depth industry knowledge, high ethical standards, and a collaborative leadership style."

Dr. Copeland joined Altair Nanotechnologies in November 2007 in the role of Vice President, Operations for Altair's Power and Energy Group. His duties included leading global operations and supply chain management for Altair's lithium titanate battery and stationary power products.

"I am pleased to have the Board's confidence and am enthusiastic about continuing to lead Altair," commented Dr. Copeland. "The Board and management team have a solid understanding of both the challenges and growth opportunities that lie ahead. I am confident that Altair has the people, technology and business plan to drive the commercialization of the company's power and energy products, as well as those in life sciences and performance materials."

The company also announced the appointment of C. Robert Pedraza as Vice President, Corporate Strategy and a member of the executive management team.

Prior to joining Altair Nanotechnologies, Dr. Copeland was the founder of T.M. Copeland Associates, an engineering, technology and operations consulting firm. Prior to founding Copeland Associates, he served as Vice President of Product Development, and Research and Development for Millennium Cell, Inc., an alternative energy company.

Dr. Copeland spent much of his career with Duracell. He joined the company in 1992 as Director of Engineering for North America, and was responsible for the program leading to the development and commercialization of Duracell's on-cell battery tester. During his tenure with Duracell, he was credited with the turnaround of an ailing manufacturing facility in North Carolina and went on to lead Duracell's largest plant in North America, with over 1,000 employees. When Gillette acquired the company, Dr. Copeland relocated to Boston as the company's Director of Product Development.

Dr. Copeland began his professional career with the DuPont Company in research and development at the company's Experimental Station in Wilmington, DE. His successes at DuPont led to roles in international marketing and manufacturing, and resulted in his appointment as Manufacturing Manager responsible for the output of several plants in North America.

Dr. Copeland graduated from the University of Delaware with a B.S. in Chemical Engineering. He earned a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology, with a minor in law.


Altairnano is an innovator and supplier of advanced novel, ceramic nanomaterials. A seasoned management team complements Altairnano's leading edge scientists, with substantial experience in commercializing innovative, disruptive technologies. The company has developed nanomaterials for the alternative energy, life sciences and performance materials markets based on its proprietary manufacturing process. This process also provides the foundation for its innovative AHP pigment process. For more information visit:

Forward-Looking Statements

This release may contain forward-looking statements as well as historical information. Forward-looking statements, which are included in accordance with the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, may involve risks, uncertainties and other factors that may cause the Altairnano's actual results and performance in future periods to be materially different from any future results or performance suggested by the forward-looking statements in this release. These risks and uncertainties include, without limitation, the risks that development of any the early-stage products referred to in this release will not be completed for technical, business or other reasons; that any products under development or in the early commercial stages will not perform as expected in future testing or commercial applications; that one or more of the joint development partners or customers may proceed slowly with, or abandon, development or commercialization efforts for any of various reasons, including concerns with the feasibility of the product or the financial viability of continuing with our products or their product; that sales of commercialized Altairnano products may not reach expected levels for one or more reasons, including the failure of end products to perform as expected or the introduction of a superior product; and that costs associated with the proposed products may exceed revenues. In general, Altairnano is, and expects to be in the immediate future, dependent upon funds generated from sales of securities, grants, testing agreements, and licensing agreements to fund its testing, development and ongoing operations. In addition, other risks are identified in the company's most recent Annual Report on Form 10-K filed with the SEC. Such forward-looking statements speak only as of the date of this release. The company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any changes in company expectations or results or any change in events.

Contact Information

  • Institutional Investors:
    C. Robert Pedraza
    Vice President, Corporate Strategy
    Altair Nanotechnologies Inc.
    Email Contact

    Individual Investors:
    Marty Tullio
    Managing Partner
    McCloud Communications, LLC
    Email Contact